Literature DB >> 15540477

Acute postoperative hypertension: a review of therapeutic options.

Curtis E Haas1, Jaclyn M LeBlanc.   

Abstract

PURPOSE: The pathophysiology and treatment of acute postoperative hypertension (APH) are discussed.
SUMMARY: APH is a significant elevation in arterial blood pressure (BP) during the immediate postoperative period. The predominant underlying mechanism appears to be sympathetic activation. APH may lead to serious neurologic, cardiovascular, or surgical-site complications and often requires intervention and management. Postoperative hypertension lasts less than six hours in most patients. Reversible or treatable causes of hypertension, including pain, anxiety, hypothermia, and hypoxemia, should be considered and treated before the implementation of antihypertensive therapy. The ideal agent for treating APH is intravenously administered, is fast acting, and has a short duration of action, allowing the rapid and safe adjustment of therapy to achieve a targeted BP range. Sodium nitroprusside has long been considered the standard therapy and has many of the ideal characteristics. However, because of the need for invasive hemodynamic monitoring and concerns about toxicity in patients given sodium nitroprusside, several newer agents may be preferable in routine clinical practice. Labetalol, nicardipine, and nitroglycerin have been widely studied or used. Hydralazine, esmolol, fenoldopam, angiotensin-converting-enzyme inhibitors, and clonidine may also be useful treatment options.
CONCLUSION: When treatment of APH is necessary, therapy should be individualized for the patient. No one agent is preferred, but effective options include sodium nitroprusside, nitroglycerin, labetalol, and nicardipine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15540477

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  15 in total

1.  Comparison of Clevidipine Versus Sodium Nitroprusside for the Treatment of Postoperative Hypertension in Cardiac Surgery Patients.

Authors:  Natalie A Freiberger; Katie B Tellor; Alison M Stevens
Journal:  Hosp Pharm       Date:  2016-06

2.  Management of hypertension in patients undergoing surgery.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-05

3.  Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs.

Authors:  C A Bloom; M A Labato; S Hazarika; M H Court
Journal:  J Vet Pharmacol Ther       Date:  2011-07-06       Impact factor: 1.786

4.  Examining the Use of Sodium Nitroprusside in Coronary Artery Bypass Grafting: Is the Benefit Worth the Cost?

Authors:  Caitlin M Gibson; Sondra Davis; Darien Bradford
Journal:  Hosp Pharm       Date:  2017-07-30

5.  Therapeutic Interchange of Clevidipine For Sodium Nitroprusside in Cardiac Surgery.

Authors:  Joseph E Cruz; Zachariah Thomas; David Lee; David M Moskowitz; Jeff Nemeth
Journal:  P T       Date:  2016-10

Review 6.  Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 7.  Severe hypertension in children and adolescents: pathophysiology and treatment.

Authors:  Joseph T Flynn; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2008-10-07       Impact factor: 3.714

8.  A comparison of nicardipine and labetalol for acute hypertension management following stroke.

Authors:  Xi Liu-Deryke; James Janisse; William M Coplin; Dennis Parker; Gregory Norris; Denise H Rhoney
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

9.  Intravenous clevidipine for management of hypertension.

Authors:  Alma Rivera; Elsa Montoya; Joseph Varon
Journal:  Integr Blood Press Control       Date:  2010-06-28

10.  Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial.

Authors:  Chad M Cannon; Phillip Levy; Brigitte M Baumann; Pierre Borczuk; Abhinav Chandra; David M Cline; Deborah B Diercks; Brian Hiestand; Amy Hsu; Preeti Jois; Brian Kaminski; Richard M Nowak; Jon W Schrock; Joseph Varon; W Frank Peacock
Journal:  BMJ Open       Date:  2013-03-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.